A Study to Assess the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab (Also Known as MPDL3280A or Anti-PD-L1) in Participants With Locally Advanced or Metastatic Solid Tumors

Inclusion Criteria

• Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
• Life expectancy of at least 12 weeks
• Adequate hematologic and end organ function
• Histologic documentation of locally advanced, recurrent, or metastatic incurable solid malignancy that has progressed after available standard therapy; or for which standard therapy is ineffective, intolerable, or considered inappropriate; or for which a clinical trial of an investigational agent is recognized standard of care
• Tumor specimen availability
• Measurable disease according to RECIST v1.1

Exclusion Criteria

• Any anti-cancer therapy, whether investigational or approved, including chemotherapy, hormonal therapy, or radiotherapy, within 3 weeks prior to initiation of study treatment
• Malignancies other than disease under study within 5 years prior to D1 of C1
• Primary central nervous system (CNS) malignancy, or untreated/active CNS metastases
• History of leptomeningeal disease
• History of idiopathic pulmonary fibrosis, pneumonitis (including drug-induced), organizing pneumonia, or evidence of active pneumonitis on screening chest computed tomography scan; history of radiation pneumonitis in the radiation field (fibrosis) is permitted
• History of autoimmune disease
• Positive human immunodeficiency virus test result
• Active hepatitis B, hepatitis C, or tuberculosis
• Severe infection within 4 weeks prior to D1 of C1
• Prior allogeneic bone marrow or solid organ transplantation
• Significant cardiovascular disease
• Known clinically significant liver disease